The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
Official Title: Multicenter Phase 1b/2 Trial Testing Neoadjuvant Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma - MARIANE
Study ID: NCT06240143
Brief Summary: This open label, single country trial will test if local injection of low-dose ipilimumab and nivolumab, is safe and reduces the sentinel node positivity in high-risk stage II melanoma patients.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Amsterdam University Medical Center, Amsterdam, , Netherlands
Antoni van Leeuwenhoek Hospital, Amsterdam, , Netherlands
University Medical Center Groningen, Groningen, , Netherlands
Leiden University Medical Center, Leiden, , Netherlands
Erasmus University Medical Center, Rotterdam, , Netherlands
University Medical Center Utrecht, Utrecht, , Netherlands
Name: Christian Blank, Prof
Affiliation: Medical oncologist/researcher
Role: PRINCIPAL_INVESTIGATOR